Evidence from clinical trials and real-world registries supports THC-based medical cannabis products for chronic neuropathic pain and balanced THC/CBD products for MS spasticity, with generally mild, transient side effects and little dependence risk.
Clinicians considering prescribing medical cannabis, patients exploring treatment options, and health policymakers evaluating medical cannabis programs.
What the researchers found
THC-predominant and balanced THC/CBD products showed the strongest evidence for chronic neuropathic pain. Balanced products were also effective for MS spasticity. Most products showed symptomatic benefits for anxiety, nausea, and sleep. Adverse effects were mostly non-serious, transient, and dose-dependent. Clinical studies found little evidence of dependence potential, contrasting with recreational use data.
Why it matters
The review distinguishes between THC-predominant, balanced, and CBD-predominant products, providing clinicians with practical guidance on which formulations have the best evidence for which conditions.
The numbers in context
THC-predominant and balanced products supported for chronic neuropathic pain. Balanced products effective for MS spasticity. Symptomatic improvements in anxiety, nausea, and sleep across product types. Adverse effects mostly non-serious and transient.
How the study worked
Narrative review evaluating published evidence from randomized controlled trials, other controlled studies, and observational real-world registry studies on the clinical benefits, safety, and dependence potential of cannabis-based medicinal products.
What this study cannot tell us
Narrative review methodology allows selective evidence inclusion. Observational registry data may have reporting bias. Most evidence comes from short-to-medium term studies. Comparison across different products and formulations is inherently difficult.
How to read the evidence
Synthesizes evidence from multiple study types including RCTs and real-world registries, but narrative review methodology limits systematic rigor.
When this study was published
2024 publication.
The bigger picture
As medical cannabis programs expand globally, clinicians need evidence-based guidance on product selection. This review moves beyond the binary 'cannabis works/doesn't work' debate to differentiate between product types and indications.
Questions still open
- Can standardized dosing protocols for specific product types improve consistency of clinical outcomes?
- How does the dependence profile of medical cannabis compare to other chronic pain medications over multi-year use?
Common questions
Which type of medical cannabis product works best?
Is medical cannabis addictive?
Read the original research
Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts.
Pain and therapy, 13(5), 1063-1094
Citation
Mick, Gérard; Douek, Pascal. (2024). Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts.. Pain and therapy, 13(5), 1063-1094. https://doi.org/10.1007/s40122-024-00643-0
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk